{"id":4397,"date":"2026-11-16T09:00:00","date_gmt":"2026-11-16T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4397"},"modified":"2026-11-18T21:45:36","modified_gmt":"2026-11-19T01:45:36","slug":"european-commission-authorizes-daraxonrasib-in-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4397","title":{"rendered":"European Commission Authorizes Daraxonrasib in Pancreatic Cancer"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Revolution_Medicines_Rasonque_Therapeutic_Indications-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4406\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Revolution_Medicines_Rasonque_Therapeutic_Indications-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Revolution_Medicines_Rasonque_Therapeutic_Indications-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Revolution_Medicines_Rasonque_Therapeutic_Indications-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Revolution_Medicines_Rasonque_Therapeutic_Indications-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261118_Revolution_Medicines_Rasonque_Therapeutic_Indications.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Revolution Medicines<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>European Commission marketing authorization (previously missed 16 Nov event)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Oral RAS(ON) multi-selective inhibitor<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Rasonque (daraxonrasib)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>RAS(ON)<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Metastatic pancreatic adenocarcinoma<\/p>\n<h4>Summary<\/h4>\n<p>The European Commission granted marketing authorization on November 16 for Rasonque, daraxonrasib, as monotherapy in adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy. The Union Register confirms the indication and ten years of orphan market exclusivity. This is an authorization, not immediate reimbursed access in every country.<\/p>\n<p>The approval followed the randomized Phase 3 RASolute 302 study. The EU product annex reports overall-population median survival of 13.2 months in 248 daraxonrasib patients versus 6.7 months in 252 investigator-choice chemotherapy patients, HR 0.40, 95% CI 0.30\u20130.53, at the February 10 primary cutoff. The peer-reviewed NEJM paper appeared online May 31, months before the November decision. The US regulatory status is separate.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> a large randomized survival difference and broad label irrespective of identified RAS mutation support a meaningful new treatment option after prior therapy and a strong commercial validation of RAS(ON) inhibition.<\/p>\n<p><strong>Interpretation B:<\/strong> trial-selected patients, comparator mix and access constraints could narrow real-world benefit; early survival follow-up and cross-region care patterns still matter. Country-specific health technology assessment, pricing and reimbursement determine practical EU uptake. Toxicities include rash, diarrhea, stomatitis, nausea and vomiting, so adherence and tolerability need real-world surveillance. Broad label does not prove equal efficacy across every genotype or line. Competitive displacement versus chemotherapy is supported by the trial, but head-to-head positioning against future targeted regimens remains untested.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Metastatic pancreatic adenocarcinoma has limited later-line options. Daraxonrasib is an oral RAS(ON) multi-selective inhibitor that forms a cyclophilin A complex to disrupt downstream RAS effector signaling. It is a targeted small molecule, not an antibody or cell therapy.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Commission register, decision and annex verify authorization, indication and trial numbers.<\/li>\n<li>Missing: country launch dates, payer decisions, long-term survival and real-world genotype outcomes.<\/li>\n<li>Upgrade: maintained OS separation with longer follow-up and broad reimbursed access.<\/li>\n<li>Downgrade: marked toxicity-related discontinuation or poor generalizability.<\/li>\n<li>Falsifier of universal-genotype interpretation: clear nonbenefiting molecular subgroup.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The authorization converts an established randomized efficacy result into a European regulatory and access signal; the actual patient reach remains country dependent.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 5 of 5. Signal Direction: positive. Confidence in Facts: High. Confidence in Interpretation: Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The European Commission granted marketing authorization on November 16 for Rasonque, daraxonrasib, as monotherapy in adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy. The Union Register confirms the indication and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4406,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[438,167,166],"class_list":["post-4397","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-daraxonrasib","tag-pancreatic-cancer","tag-revolution-medicines"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4397"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4397\/revisions"}],"predecessor-version":[{"id":4423,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4397\/revisions\/4423"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4406"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}